Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Towards a New Era: Is Coronary Artery Disease Reversible?

      Cardiology

      S. Karger AG

      Atherosclerosis, Cholesterol, Lipid-lowering trials, Regression

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is increasing evidence that conventional lipid-lowering therapy can arrest the progression of coronary atherosclerosis. Trials are now under way to determine whether more radical reduction of low-density-lipoprotein cholesterol will reverse atherosclerosis and lead to regression of coronary lesions. The ability to effect such reductions has been markedly enhanced by the introduction into clinical practice of the 3-hydroxy-3-methylglutaryl coen-zyme A reductase inhibitors.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-5278-3
          978-3-318-00092-4
          0008-6312
          1421-9751
          1990
          1990
          12 November 2008
          : 77
          : Suppl 4
          : 66-69
          Affiliations
          MRC Lipoprotein Team, Hammersmith Hospital, London, UK
          Article
          174685 Cardiology 1990;77:66–69
          10.1159/000174685
          2073674
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          HMG CoA Reductase Inhibitors: New Horizons in the Management of Hypercholesterolemia

          Comments

          Comment on this article